Global T-cell Therapy Market by Therapy (Tumor-Infiltrating Lymphocytes, CAR T-cell), by Indication (Hematologic Malignancies, Solid Tumors) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global T-cell therapy market was valued at USD4.6 billion in 2020. It is expected to grow at a compound annual rate (CAGR of 20.2%) between 2021 and 2028. Many companies have changed their business models, shifting from developing small molecule- and protein-based therapies to adoptive therapies, following approvals by Yescarta and Kymriah. This has fueled strategic investments by both the private and public agencies in this area, which has pushed the market for T cell therapy.
In the next few years, T-cell therapy companies will face increased competition due to increasing approvals and expanding manufacturing capabilities. Kite Pharma's Tecartus, the only CAR–T therapeutic product for mantle-cell lymphoma, received a marketing authorization from the European Medicine Agency in December 2020.
The global COVID-19 epidemic has also prompted investment in the deciphering of the use of T-cell therapies for viral infection research. In December 2020, a study showed the potential for this therapy to be used to treat COVID-19 high-risk patients. In September 2020, the U.S. FDA approved the IND application for ALVR109 in order to treat COVID-19 sufferers. This will likely increase the use of T-cell therapies for viral infections.
The majority of cancer immunotherapy currently uses a T-cell-based method due to its higher success rate. More than 350 clinical trials for CAR-T have been registered in China as of June 2020. These numbers show the increasing importance of Chimeric Antigen Receptor Therapy in cancer treatment. To improve their market position in the near future, most operating players are now investing in CD19-CAR-T therapies.
CAR-T therapies are thriving because of the growing gene therapy market. This space will continue to grow with increasing investment in gene therapy. Novartis AG and other companies are actively exploring the potential for CAR-T-based gene therapy for multiple chronic indications.
COVID-19 Impact: The market's revenue is boosted by the success of Kymriah & Yescarta
|
Pandemic Impact |
Outlook after COVID |
|
The commercial market segment is driven by the July 2020 approval of Tecartus for mantle cell lymphoma treatment. |
A number of major players have begun to adopt digital alternatives to manage cell therapy supply chains due to the current uncertainty in the supply chain as a result of the COVID-19 pandemic. This trend is expected to continue into the future. |
|
CAR-T cells therapy are the main driving segment. In 2020, there was a 37% increase in year-over-year growth due to Kymriah and Yescarta as well as other piepilne program candidates. |
TrakCel would see an increase in strategic alliances between therapy developers and supply chain solution providers to help accelerate and achieve supply chains harmonization within closed-system manufacturing. |
Modality Insights
Due to the large number of products currently in clinical development, the research segment was the dominant market for T-cell treatment. It accounted for over 75.0% revenue share in 2020. CAR-T therapy is a preferred method for cancer management and a large number of research institutions such as Mayo Clinic have been involved in its development.
Many operating entities collaborate with researchers around the world, which has led to a shift in focus to accelerate the development of CAR–T therapies and expand the therapeutic applications landscape. In October 2020, Immuneel Therapeutics partnered with Institut d'Investigacions Biomediques August Pi i Sunyer et Hospital Clinic de Barcelona to develop and commercialize CAR-T therapy for India.
Regulators are focusing their efforts to promote the commercial use these therapies in hospital and clinical settings. The Centers for Medicare and Medicaid Service (CMS), in August 2020, established policies for reimbursement and coverage for CAR-T cells therapy. The policy raised the amount of payment to 65% of total cost. This would encourage commercial revenue growth.
Therapy Type Insights
CAR T cell therapy was the dominant market segment for T-cell therapy in 2020. It accounted for the largest revenue share at 82.0%. This is due to an exponential increase in CAR-T therapies clinical trials and increasing involvement by key players. There are many new players and academic institutions that conduct clinical trials for CAR–T therapeutic products for different indications. This supports the market's dominance.
CAR-T therapy manufacturing has made it easier to increase the use of these therapies for various types of cancer. New approaches, such as the second-generation, next generation CAR-T immunotherapy, may be able to overcome resistance and side effects, thereby increasing organic revenue generation.
Because of their potential to treat solid tumors, T-cell receptor-based treatments ranked second in the global space. This market is becoming increasingly popular for the treatment of melanomas. Adaptimmune, in partnership with GlaxoSmithKline, focuses on TCR treatment for melanoma.
Indication Insights
The market for T-cell therapy was dominated by the segment of hematologic malignancies in 2020. It accounted for 49.0% of the revenue share. CAR-T cell therapies are primarily used to treat hematological cancers such as lymphoma and leukemia. The segment will see high competition due to the large number of market players and the high fixed costs associated with autologous cell production.
CAR-T cell therapies have made significant advances in hematological malignancies. This has led to segment saturation in terms the number of market players in this segment. To capitalize on untapped markets, many competitors have shifted their focus to the development of solid tumor treatments. Operational key stakeholders have lucrative opportunities in the development of an affordable, effective treatment for solid tumors.
The number of T-cell therapies for viral infections like HIV and COVID-19 has increased. Many CARs that target viral infections have made remarkable progress in the last few years. The clinical trial for anti-HIV CAR T cell therapy has been completed, while others like HCV and HBV are still in preclinical development. This will increase revenue for non-cancer indications.
Regional Insights
North America was the dominant market for T-cell therapy in 2020, accounting for around 40% of the total revenue. Strong research and a strong commercial base, combined with the high number of clinical trials for T-cell therapies being conducted in the U.S. have all contributed greatly to the dominance in this market.
The market has seen significant growth due to the growing number of regulatory approvals in Canada and the U.S., as well as the changing reimbursement system in the region. The regional market is also supported by the existence of numerous medical centers that offer CAR-T cells therapies.
China has been a promising market for CAR–T therapies in recent years. It hosts the largest number of clinical trials related to these therapies. The country has shown the highest CAGR due to its focus on reforms and government investment.
Market Share Insights & Key Companies
It is expected that the T-cell therapy market will be more competitive due to the increasing number of companies involved with the development of CAR–T therapies. Kite Pharma AG and Novartis AG are the leaders in T-cell therapy innovation and product development.
Juno Therapeutics and Adaptimmune are among the companies that are currently involved in developing T-cell therapies for various oncology indications.
Moreover, increasing investment flows have led to the entry of traditional drug developers like Merck KGaA, Pfizer and Amgen into this market. Sanofi's acquisition of Kiadis Pharma shows the increasing interest of international pharmaceutical companies in this area. The market leader in T-cell therapy is:
-
Novartis AG
-
Merck KGaA
-
Gilead Sciences Inc.
-
TCR2 Therapeutics Inc
-
Bluebird Bio Inc.
-
Sorrento Therapeutics
-
Fate Therapeutics
-
Pfizer Inc.
-
Amgen
-
Celgene Corporation
Up Market Research published a new report titled “T-cell Therapy Market research report which is segmented by Therapy (Tumor-Infiltrating Lymphocytes, CAR T-cell), by Indication (Hematologic Malignancies, Solid Tumors), By Players/Companies Gilead Sciences Inc, Sorrento Therapeutics, TCR2 Therapeutics Inc, Novartis AG, Amgen, Fate Therapeutics, Bluebird Bio Inc, Pfizer Inc, Celgene Corporation, Merck KGaA”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | T-cell Therapy Market Research Report |
| By Therapy | Tumor-Infiltrating Lymphocytes, CAR T-cell |
| By Indication | Hematologic Malignancies, Solid Tumors |
| By Companies | Gilead Sciences Inc, Sorrento Therapeutics, TCR2 Therapeutics Inc, Novartis AG, Amgen, Fate Therapeutics, Bluebird Bio Inc, Pfizer Inc, Celgene Corporation, Merck KGaA |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 204 |
| Number of Tables & Figures | 143 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global T-cell Therapy Market Report Segments:
The market is segmented by Therapy (Tumor-Infiltrating Lymphocytes, CAR T-cell), by Indication (Hematologic Malignancies, Solid Tumors).
T-cell Therapy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the T-cell Therapy Market
Overview of the regional outlook of the T-cell Therapy Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The T-cell Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of T-cell Therapy Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Tumor-Infiltrating Lymphocytes
2. CAR T-cell
7. By Indication:1. Hematologic Malignancies
2. Solid Tumors
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the T-cell Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the T-cell Therapy Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 T-cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 T-cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 T-cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the T-cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global T-cell Therapy Market Size & Forecast, 2018-2028
4.5.1 T-cell Therapy Market Size and Y-o-Y Growth
4.5.2 T-cell Therapy Market Absolute $ Opportunity
Chapter 5 Global T-cell Therapy Market Analysis and Forecast by Therapy
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapy
5.1.2 Basis Point Share (BPS) Analysis by Therapy
5.1.3 Absolute $ Opportunity Assessment by Therapy
5.2 T-cell Therapy Market Size Forecast by Therapy
5.2.1 Tumor-Infiltrating Lymphocytes
5.2.2 CAR T-cell
5.3 Market Attractiveness Analysis by Therapy
Chapter 6 Global T-cell Therapy Market Analysis and Forecast by Indication
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Indication
6.1.2 Basis Point Share (BPS) Analysis by Indication
6.1.3 Absolute $ Opportunity Assessment by Indication
6.2 T-cell Therapy Market Size Forecast by Indication
6.2.1 Hematologic Malignancies
6.2.2 Solid Tumors
6.3 Market Attractiveness Analysis by Indication
Chapter 7 Global T-cell Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 T-cell Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America T-cell Therapy Analysis and Forecast
9.1 Introduction
9.2 North America T-cell Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America T-cell Therapy Market Size Forecast by Therapy
9.6.1 Tumor-Infiltrating Lymphocytes
9.6.2 CAR T-cell
9.7 Basis Point Share (BPS) Analysis by Therapy
9.8 Absolute $ Opportunity Assessment by Therapy
9.9 Market Attractiveness Analysis by Therapy
9.10 North America T-cell Therapy Market Size Forecast by Indication
9.10.1 Hematologic Malignancies
9.10.2 Solid Tumors
9.11 Basis Point Share (BPS) Analysis by Indication
9.12 Absolute $ Opportunity Assessment by Indication
9.13 Market Attractiveness Analysis by Indication
Chapter 10 Europe T-cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe T-cell Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe T-cell Therapy Market Size Forecast by Therapy
10.6.1 Tumor-Infiltrating Lymphocytes
10.6.2 CAR T-cell
10.7 Basis Point Share (BPS) Analysis by Therapy
10.8 Absolute $ Opportunity Assessment by Therapy
10.9 Market Attractiveness Analysis by Therapy
10.10 Europe T-cell Therapy Market Size Forecast by Indication
10.10.1 Hematologic Malignancies
10.10.2 Solid Tumors
10.11 Basis Point Share (BPS) Analysis by Indication
10.12 Absolute $ Opportunity Assessment by Indication
10.13 Market Attractiveness Analysis by Indication
Chapter 11 Asia Pacific T-cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific T-cell Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific T-cell Therapy Market Size Forecast by Therapy
11.6.1 Tumor-Infiltrating Lymphocytes
11.6.2 CAR T-cell
11.7 Basis Point Share (BPS) Analysis by Therapy
11.8 Absolute $ Opportunity Assessment by Therapy
11.9 Market Attractiveness Analysis by Therapy
11.10 Asia Pacific T-cell Therapy Market Size Forecast by Indication
11.10.1 Hematologic Malignancies
11.10.2 Solid Tumors
11.11 Basis Point Share (BPS) Analysis by Indication
11.12 Absolute $ Opportunity Assessment by Indication
11.13 Market Attractiveness Analysis by Indication
Chapter 12 Latin America T-cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America T-cell Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America T-cell Therapy Market Size Forecast by Therapy
12.6.1 Tumor-Infiltrating Lymphocytes
12.6.2 CAR T-cell
12.7 Basis Point Share (BPS) Analysis by Therapy
12.8 Absolute $ Opportunity Assessment by Therapy
12.9 Market Attractiveness Analysis by Therapy
12.10 Latin America T-cell Therapy Market Size Forecast by Indication
12.10.1 Hematologic Malignancies
12.10.2 Solid Tumors
12.11 Basis Point Share (BPS) Analysis by Indication
12.12 Absolute $ Opportunity Assessment by Indication
12.13 Market Attractiveness Analysis by Indication
Chapter 13 Middle East & Africa (MEA) T-cell Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) T-cell Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) T-cell Therapy Market Size Forecast by Therapy
13.6.1 Tumor-Infiltrating Lymphocytes
13.6.2 CAR T-cell
13.7 Basis Point Share (BPS) Analysis by Therapy
13.8 Absolute $ Opportunity Assessment by Therapy
13.9 Market Attractiveness Analysis by Therapy
13.10 Middle East & Africa (MEA) T-cell Therapy Market Size Forecast by Indication
13.10.1 Hematologic Malignancies
13.10.2 Solid Tumors
13.11 Basis Point Share (BPS) Analysis by Indication
13.12 Absolute $ Opportunity Assessment by Indication
13.13 Market Attractiveness Analysis by Indication
Chapter 14 Competition Landscape
14.1 T-cell Therapy Market: Competitive Dashboard
14.2 Global T-cell Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences Inc
14.3.2 Sorrento Therapeutics
14.3.3 TCR2 Therapeutics Inc
14.3.4 Novartis AG
14.3.5 Amgen
14.3.6 Fate Therapeutics
14.3.7 Bluebird Bio Inc
14.3.8 Pfizer Inc
14.3.9 Celgene Corporation
14.3.10 Merck KGaA
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 T-cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 T-cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 T-cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the T-cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global T-cell Therapy Market Size & Forecast, 2018-2028
4.5.1 T-cell Therapy Market Size and Y-o-Y Growth
4.5.2 T-cell Therapy Market Absolute $ Opportunity
Chapter 5 Global T-cell Therapy Market Analysis and Forecast by Therapy
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapy
5.1.2 Basis Point Share (BPS) Analysis by Therapy
5.1.3 Absolute $ Opportunity Assessment by Therapy
5.2 T-cell Therapy Market Size Forecast by Therapy
5.2.1 Tumor-Infiltrating Lymphocytes
5.2.2 CAR T-cell
5.3 Market Attractiveness Analysis by Therapy
Chapter 6 Global T-cell Therapy Market Analysis and Forecast by Indication
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Indication
6.1.2 Basis Point Share (BPS) Analysis by Indication
6.1.3 Absolute $ Opportunity Assessment by Indication
6.2 T-cell Therapy Market Size Forecast by Indication
6.2.1 Hematologic Malignancies
6.2.2 Solid Tumors
6.3 Market Attractiveness Analysis by Indication
Chapter 7 Global T-cell Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 T-cell Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America T-cell Therapy Analysis and Forecast
9.1 Introduction
9.2 North America T-cell Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America T-cell Therapy Market Size Forecast by Therapy
9.6.1 Tumor-Infiltrating Lymphocytes
9.6.2 CAR T-cell
9.7 Basis Point Share (BPS) Analysis by Therapy
9.8 Absolute $ Opportunity Assessment by Therapy
9.9 Market Attractiveness Analysis by Therapy
9.10 North America T-cell Therapy Market Size Forecast by Indication
9.10.1 Hematologic Malignancies
9.10.2 Solid Tumors
9.11 Basis Point Share (BPS) Analysis by Indication
9.12 Absolute $ Opportunity Assessment by Indication
9.13 Market Attractiveness Analysis by Indication
Chapter 10 Europe T-cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe T-cell Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe T-cell Therapy Market Size Forecast by Therapy
10.6.1 Tumor-Infiltrating Lymphocytes
10.6.2 CAR T-cell
10.7 Basis Point Share (BPS) Analysis by Therapy
10.8 Absolute $ Opportunity Assessment by Therapy
10.9 Market Attractiveness Analysis by Therapy
10.10 Europe T-cell Therapy Market Size Forecast by Indication
10.10.1 Hematologic Malignancies
10.10.2 Solid Tumors
10.11 Basis Point Share (BPS) Analysis by Indication
10.12 Absolute $ Opportunity Assessment by Indication
10.13 Market Attractiveness Analysis by Indication
Chapter 11 Asia Pacific T-cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific T-cell Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific T-cell Therapy Market Size Forecast by Therapy
11.6.1 Tumor-Infiltrating Lymphocytes
11.6.2 CAR T-cell
11.7 Basis Point Share (BPS) Analysis by Therapy
11.8 Absolute $ Opportunity Assessment by Therapy
11.9 Market Attractiveness Analysis by Therapy
11.10 Asia Pacific T-cell Therapy Market Size Forecast by Indication
11.10.1 Hematologic Malignancies
11.10.2 Solid Tumors
11.11 Basis Point Share (BPS) Analysis by Indication
11.12 Absolute $ Opportunity Assessment by Indication
11.13 Market Attractiveness Analysis by Indication
Chapter 12 Latin America T-cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America T-cell Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America T-cell Therapy Market Size Forecast by Therapy
12.6.1 Tumor-Infiltrating Lymphocytes
12.6.2 CAR T-cell
12.7 Basis Point Share (BPS) Analysis by Therapy
12.8 Absolute $ Opportunity Assessment by Therapy
12.9 Market Attractiveness Analysis by Therapy
12.10 Latin America T-cell Therapy Market Size Forecast by Indication
12.10.1 Hematologic Malignancies
12.10.2 Solid Tumors
12.11 Basis Point Share (BPS) Analysis by Indication
12.12 Absolute $ Opportunity Assessment by Indication
12.13 Market Attractiveness Analysis by Indication
Chapter 13 Middle East & Africa (MEA) T-cell Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) T-cell Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) T-cell Therapy Market Size Forecast by Therapy
13.6.1 Tumor-Infiltrating Lymphocytes
13.6.2 CAR T-cell
13.7 Basis Point Share (BPS) Analysis by Therapy
13.8 Absolute $ Opportunity Assessment by Therapy
13.9 Market Attractiveness Analysis by Therapy
13.10 Middle East & Africa (MEA) T-cell Therapy Market Size Forecast by Indication
13.10.1 Hematologic Malignancies
13.10.2 Solid Tumors
13.11 Basis Point Share (BPS) Analysis by Indication
13.12 Absolute $ Opportunity Assessment by Indication
13.13 Market Attractiveness Analysis by Indication
Chapter 14 Competition Landscape
14.1 T-cell Therapy Market: Competitive Dashboard
14.2 Global T-cell Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead Sciences Inc
14.3.2 Sorrento Therapeutics
14.3.3 TCR2 Therapeutics Inc
14.3.4 Novartis AG
14.3.5 Amgen
14.3.6 Fate Therapeutics
14.3.7 Bluebird Bio Inc
14.3.8 Pfizer Inc
14.3.9 Celgene Corporation
14.3.10 Merck KGaA
Segments Covered in the Report
The global T-cell Therapy market has been segmented based on
By Therapy
The global T-cell Therapy market has been segmented based on
By Therapy
- Tumor-Infiltrating Lymphocytes
- CAR T-cell
- Hematologic Malignancies
- Solid Tumors
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Gilead Sciences Inc
- Sorrento Therapeutics
- TCR2 Therapeutics Inc
- Novartis AG
- Amgen
- Fate Therapeutics
- Bluebird Bio Inc
- Pfizer Inc
- Celgene Corporation
- Merck KGaA
Our Clients
Related Reports
Some other reports from this category!
